Keywords: Amgen, Mustafa Nevzat Pharma, Turkey, M&A
Amgen acquires Turkish drugmaker Mustafa Nevzat for $700 million
Article | 26 April 2012
Global biotech giant Amgen (Nasdaq: AMGN) has reached agreement to acquire 95.6% of Mustafa Nevzat Pharmaceuticals (MN), a privately-held Turkish pharmaceutical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
